Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Werner

Showing results (121-130 of 151) with videos related to

Pageof 16
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PETJan-Michael Werner, Johannes Weller, Garry Ceccon, et al.
Cancers|March 10, 2022
Oncologic Outcome and Immune Responses of Radiotherapy with Anti-PD-1 Treatment for Brain Metastases Regarding Timing and Benefiting SubgroupsMaike Trommer, Anne Adams, Eren Celik, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2022
Cost Effectiveness of <sup>18</sup>F-FET PET for Early Treatment Response Assessment in Glioma Patients After Adjuvant Temozolomide ChemotherapyJurij Rosen, Garry Ceccon, Elena K Bauer, et al.
Neuro-Oncology Advances|March 14, 2025
Functional connectivity between tumor region and resting-state networks as imaging biomarker for overall survival in recurrent gliomas diagnosed by <i>O</i>-(2-[<sup>18</sup>F]fluoroethyl)-l-tyrosine PETMichel Friedrich, Jan-Michael Werner, Joachim P Steinbach, et al.
Biologicals : Journal of the International Association of Biological Standardization|July 28, 2016
Report of the International Regulatory Forum on Human Cell Therapy and Gene Therapy ProductsTakao Hayakawa, Ian Harris, Jeewon Joung, et al.
Nature Communications|October 21, 2015
Landscape simplification filters species traits and drives biotic homogenizationSagrario Gámez-Virués, David J Perović, Martin M Gossner, et al.
JCO Oncology Practice|December 11, 2024
Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical TrialsJulia Blanter, Grace Van Hyfte, Maham Ahmad, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 17, 2025
Borderline Findings in <i>O</i>-(2-[<sup>18</sup>F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical PracticeKarl-Josef Langen, Gabriele Stoffels, Christian P Filss, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|February 8, 2018
Postoperative rehabilitation after deep brain stimulation surgery for movement disordersNiels Allert, Binith Cheeran, Günther Deuschl, et al.
Elife|December 28, 2017
Transcription-factor-dependent enhancer transcription defines a gene regulatory network for cardiac rhythmXinan H Yang, Rangarajan D Nadadur, Catharina Re Hilvering, et al.
Pageof 16

Showing results (121-130 of 151) with videos related to

Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2021
Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PETJan-Michael Werner, Johannes Weller, Garry Ceccon, et al.
Cancers|March 10, 2022
Oncologic Outcome and Immune Responses of Radiotherapy with Anti-PD-1 Treatment for Brain Metastases Regarding Timing and Benefiting SubgroupsMaike Trommer, Anne Adams, Eren Celik, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2022
Cost Effectiveness of <sup>18</sup>F-FET PET for Early Treatment Response Assessment in Glioma Patients After Adjuvant Temozolomide ChemotherapyJurij Rosen, Garry Ceccon, Elena K Bauer, et al.
Neuro-Oncology Advances|March 14, 2025
Functional connectivity between tumor region and resting-state networks as imaging biomarker for overall survival in recurrent gliomas diagnosed by <i>O</i>-(2-[<sup>18</sup>F]fluoroethyl)-l-tyrosine PETMichel Friedrich, Jan-Michael Werner, Joachim P Steinbach, et al.
Biologicals : Journal of the International Association of Biological Standardization|July 28, 2016
Report of the International Regulatory Forum on Human Cell Therapy and Gene Therapy ProductsTakao Hayakawa, Ian Harris, Jeewon Joung, et al.
Nature Communications|October 21, 2015
Landscape simplification filters species traits and drives biotic homogenizationSagrario Gámez-Virués, David J Perović, Martin M Gossner, et al.
JCO Oncology Practice|December 11, 2024
Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical TrialsJulia Blanter, Grace Van Hyfte, Maham Ahmad, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 17, 2025
Borderline Findings in <i>O</i>-(2-[<sup>18</sup>F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical PracticeKarl-Josef Langen, Gabriele Stoffels, Christian P Filss, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|February 8, 2018
Postoperative rehabilitation after deep brain stimulation surgery for movement disordersNiels Allert, Binith Cheeran, Günther Deuschl, et al.
Elife|December 28, 2017
Transcription-factor-dependent enhancer transcription defines a gene regulatory network for cardiac rhythmXinan H Yang, Rangarajan D Nadadur, Catharina Re Hilvering, et al.
Pageof 16